Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ

Table 3 Change in biomarkers with anti-estrogenic treatment

	Controls (n = 18)	All Cases (n = 23)		Postmenopausal Cases (n = 9)		Premenopausal Cases (n = 14)
Biomarker	Mean change¹	Mean change	p ²	Mean change	p	Mean change	p
ER (H-score)³	-55.5 ± 22.2	-92.1 ± 23.7	0.21	-113.8 ± 26.2	0.07	-78.2 ± 35.4	0.62
PR (H-score)³	-38.8 ± 18.3	-110.1 ± 18.7	0.03	-169.2 ± 18.8	0.001	-72.1 ± 22.0	0.40
Ki-67⁴	-3.2 ± 1.7	-10.2 ± 1.8	0.007	-14.4 ± 3.6	0.013	-7.5 ± 1.6	0.037
CD68⁴	-0.06 ± 1.7	34.1 ± 8.3	<0.0001	29.4 ± 5.8	<0.0001	37.2 ± 13.2	0.002
caspase 3⁵	0.8 ± 0.7	0.1 ± 0.4	0.15	-0.1 ± 0.7	0.13	0.2 ± 0.5	0.33

¹Data shows mean increase (positive values) or mean decrease (negative values) in quantitative immunohistochemical staining between diagnostic core biopsy and surgical excision. Cases were treated with neoadjuvant anti-estrogenic therapy; controls did not undergo neoadjuvant therapy.
²Rank-sum test, controls as referent group.
³H-score is weighted measure of intensity and percentage of positive cells (see Methods).
⁴Percent of cells staining positive.
⁵Number of CD68-positive macrophages per high power field within DCIS ducts.

ISSN: 1471-2407